LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
LBT Innovations Limited Reports Earnings Results for the Full Year Ended June 30, 2024 CI
Transcript : LBT Innovations Limited, Q4 2024 Earnings Call, Aug 14, 2024
Australian Shares Rise on Bargain Hunters, Higher Oil Prices MT
LBT Innovations Bags Up to AU$4.1 Million Contract with AstraZeneca; Shares Climb 33% MT
LBT Innovations Advances Pharmaceutical Strategy of Plate System MT
Transcript : LBT Innovations Limited, Q3 2024 Earnings Call, May 08, 2024
LBT Innovations Sells APAS Independence Instrument to NovaCina MT
Australian Shares Track Gains of Wall Street Peers as Market Shrugs Off US Inflation Data MT
LBT Innovations' APAS PharmaQC Completes Primary Validation; Shares Up 79% MT
Transcript : LBT Innovations Limited, Q2 2024 Earnings Call, Feb 29, 2024
LBT Innovations Delivers APAS Hardware, Software to Thermo Fisher MT
LBT Innovations Limited Reports Earnings Results for the Half Year Ended December 31, 2023 CI
LBT Innovations Makes First Sale of APAS PharmaQC; Shares Jump 31% MT
LBT Innovations Limited Appoints Dan Hill as Non-Executive Director CI
LBT Innovations Limited Announces Retirement of Damian Lismore as Director. Effective 29 November 2023 CI
LBT Innovations Secures Approval for AU$1.7 Million Loan Restructuring MT
LBT Innovations Fully Repays Share Placement Facility MT
LBT Innovations Raising Up to AU$4.5 Million Via Entitlement Offer; Shares Down 27% MT
LBT Innovations Secures R&D Tax Refund for Fiscal Year 2023; Shares Rally 11% MT
LBT Innovations Limited Reports Earnings Results for the Full Year Ended June 30, 2023 CI
LBT Innovations Flags AU$13 Million Impairment Charge MT
LBT Innovations Limited Appoints Rebecca Wilson as Director CI
LBT Innovations Appoints Chair; Shares Jump 7% MT
LBT Innovations Limited Announces the Retirement of Simon Arkell as Non-Executive Director CI
LBT Innovations Limited Reports Earnings Results for the Half Year Ended December 31, 2022 CI
Chart LBT Innovations Limited
More charts
Logo LBT Innovations Limited
LBT Innovations Limited is a medical technology company. The Company is engaged in researching, developing and commercializing technologies for the healthcare and laboratory supply markets and manufacture and sales of the Automated Plate Assessment System (APAS Independence). Its products include APAS Independence, APAS Analysis Modules, APAS-AMR Analysis Module, and APAS PharmaQ. The APAS Independence is a platform technology that automates culture-plate screening and interpretation. The APAS Analysis Modules are the intelligent image analysis software that works together with the APAS Independence to enable the screening of microbiology culture plates. The APAS-AMR Analysis Module uses artificial intelligence mage analysis platform to read and interpret antimicrobial susceptibility tests (ASTs) for the detection of antimicrobial resistance (AMR). The APAS PharmaQC provides automated imaging, analysis and interpretation of microbiology culture plates used in environmental monitoring.
Employees
19
More about the company
  1. Stock Market
  2. Equities
  3. LBT Stock
  4. News LBT Innovations Limited
  5. LBT Innovations Bags Up to AU$4.1 Million Contract with AstraZeneca; Shares Climb 33%
-40% Limited-time offer: Our subscriptions help you unlock the best investment opportunities. Last hours!
BENEFIT NOW